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Abstract
Kaposi’s sarcoma-associated virus (KSHV) ORF50 protein induces lytic replication and activates the K8 promoter. We show that ORF50-
induced and tetradecanoyl phorbol acetate (TPA) induced K8 transcripts initiated from the same start site. A newly identified palindrome (PAL2),
containing a 12-bp response region required for ORF50-induced activation in lymphoid cells, was identified in the K8 promoter. Specific DNA
binding of bacterially expressed ORF50 was not seen with the K8 promoter despite specific binding to the PAN promoter. The new palin-
drome shared homology with a previously described ORF50 response element (50REK8 and 50RE57). We demonstrate that the new 50REK8
(50REK8-PAL2) is not the palindrome per se. Instead, the response element is buried within the right arm of the palindrome. We propose that the
complexity of the K8 response elements reflects the complexity of mechanisms used by ORF50 during viral reactivation.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Human herpesvirus 8 (Kaposi’s sarcoma-associated virus,
KSHV) is found within Kaposi’s sarcoma cells (KS) (Chang et
al., 1994; Zhong et al., 1996) and is now considered its etio-
logically agent. KS is an angiogenic proliferative disorder that
is prevalent in individuals with AIDS and other forms of
immune suppression. It is endemic in some Mediterranean
countries and certain regions of Africa. KSHV is also associ-
ated with primary effusion lymphoma (PEL) (Cesarman et al.,
1995) and multicentric Castleman’s disease (Gessain et al.,
1996; Soulier et al., 1995). Sequence analysis indicates that
KSHV is related to primate -herpesviruses, Epstein–Barr vi-
rus (EBV), and herpesvirus saimiri (HSV) (Russo et al., 1996).
-Herpesviruses establish a latent infection characterized
by limited viral gene expression. EBV is the prototypical
-herpesvirus and reactivation of the EBV lytic cascade has
been extensively studied (Adamson et al., 2000; Fleming-
ton, 2001; Hardwick et al., 1988; Holley-Guthrie et al.,
1990; Jenkins et al., 2000; Kenney et al., 1989; Miller,
1989; Quinlivan et al., 1993; Ragoczy and Miller, 1999a;
Segouffin et al., 1996; Sinclair et al., 1991; Zalani et al.,
1996). The lytic gene cascade is initiated after the expres-
sion of the EBV R and Z proteins encoded by the BRLF1
and BZLF1 genes, respectively. Both of these proteins are
transactivators and each one is necessary for full activation
of EBV early gene expression. The Z protein transactivates
the BRLF1 promoter by binding to specific Z-responsive
elements (Adamson and Kenney, 1998; Flemington and
Speck, 1990; Quinlivan et al., 1990; Rooney et al., 1989;
Sinclair et al., 1991). While R has been shown to bind to
GC-rich regions in several EBV genes (Gruffat et al., 1992;
Quinlivan et al., 1993), activation of the BZLF1 promoter is
mediated through activation of MAP-kinase pathways
rather than direct binding of R to this promoter (Adamson et
al., 2000).
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The ORF50 gene of KSHV is a positional homologue of
the EBV BRLF1 and HVS ORF50 genes (Russo et al.,
1996). The K8 gene of KSHV is a positional homologue of
the EBV BZLF1 gene (Lin et al., 1999; Seaman et al.,
1999). Transfection of latently infected PEL cell lines with
ORF50 expression vectors is sufficient to activate the lytic
cascade of gene expression from transcription of early genes
to the production of viral particles. KSHV genes which have
been examined for ORF50 responsiveness include the fol-
lowing: ORF50 (Sakakibara et al., 2001); thymidine kinase
(Zhang et al., 1998); PAN (Lukac et al., 1998; Song et al.,
2001); ORF57 (Duan et al., 2001; Lukac et al., 1998, 2001)
and K8 (Lukac et al., 1998; Seaman et al., 1999). At least
some of the ORF50 induced-gene expression is mediated by
binding to specific DNA sequences (Rta response elements,
RREs, ORF50 response element in n promoter, 50REn) in
several of these promoters.
We previously examined gene expression patterns and
gene expression controls in the ORF50 region (Seaman et
al., 1999). K8 expression is one of the earliest genes ex-
pressed following ORF50 expression. We identified two K8
transcripts and characterized the delayed-early expression
pattern of these transcripts. ORF50 expression activated
both ORF50 and K8 promoter sequences. Domain mapping
experiments revealed a 100-aa C-terminal ORF50 activation
domain. K8 promoter elements contributing to ORF50 ac-
tivation have only been partially characterized. To better
define ORF50 induction of K8 expression, we examined
ORF50 binding to the promoter and performed reporter
assays and mapping experiments. In this article, we show
that expression of ORF50 resulted in transactivation of the
K8 promoter in the absence of additional KSHV gene prod-
ucts, and the transcriptional initiation site was identical to
the site used during TPA-induced viral reactivation. A
12-bp element contained the major response region required
for ORF50-induced activation in lymphoid cells. We ex-
pressed ORF50 as a bacterial fusion protein and demon-
strated that this protein is able to bind to the response
element in the PAN promoter. Despite this, specific binding
was not seen with the K8 promoter. Sequence analysis
revealed that the 12-bp response element resided within an
inverted repeat or palindrome (PAL2). Homology between
PAL2 to a previously identified palindrome response ele-
ment (50REK8 and 50RE57 and designated PAL1 in this
article) was seen (Lukac et al., 2001; Wang et al., 2001a).
We demonstrated that the response element (50REK8-PAL2)
did not require preservation of the palindrome.
Results
Transfection of cells with pCMV-50 results in ORF50
protein production
To examine the effect of isolated ORF50 expression on
gene expression, we expressed full-length ORF50 protein
from a cDNA insert directed by the CMV immediate-early
promoter. In western blot analysis a 120-kDa band was
detected in cytoplasmic and nuclear extracts of TPA-treated
BCBL-1 cells and pCMV-ORF50 transfected Cos-7 cells
using polyclonal antibody (gift of D. Ganem) (Lukac et al.,
1998). These bands had a higher molecular weight com-
pared to in vitro translated ORF50, demonstrating posttrans-
lational processing (data not shown).
Activation of K8 promoter by ORF50 does not require
additional KSHV gene products in lymphoid cells
To determine the K8 transcription initiation site utilized
by ORF50, we performed primer extension assays. The
template clone of K8 (pK8GEN) contained a KSHV
genomic 503-bp DNA fragment from 74,348 to 76,738,
which included 503-bp upstream of the transcription start
site (74,845) used during phorpol ester induction of BCBL
cells (Fig. 1A). The transcript initiation site during TPA
induction of lytic replication from latent KSHV in BCBL-1
cells served as the positive control reaction (Fig. 1B). The
primer K8PRXT (complement of 74,932–74,950) detected a
single band in pK8GEN- and pCMV-50-transfected DG-75
cells (Fig. 1C), based on a DNA sequence ladder generated
using pK8GEN as a template and K8PRXT as a sequencing
primer. The bands seen in TPA-treated BCBL-1 cells and
pCMV-50-transfected DG-75 cells corresponded to identi-
cal transcript start sites (nucleotide 74,845). The transcrip-
tion induced by ORF 50 occurred in the absence of other
viral gene products.
K8 promoter elements responsive to ORF50 span 110
to 100 nt from the transcription start site
Serial deletions of the K8 promoter region used in the
primer extension experiments and linked to a luciferase
reporter gene were used to identify the region of the K8
promoter involved in ORF50-dependent transactivation
(Fig. 2A). -Galactoside expression from transfected ex-
pression vector was used to normalize the results for vari-
ations in transfection efficiency. Cotransfection of HeLa
cells with pCMV-50 and pK8Luc-532 resulted in a 76-fold
increase in luciferase activity. A 143-fold increase in lucif-
erase activity was observed in cells cotransfected with
pCMV-50 and pK8Luc-187. The construct with 106 bp of
upstream sequence was completely unresponsive to trans-
activation by ORF50. Removal of 187 to 146 signifi-
cantly reduced responsiveness. To confirm the significance
of the 146 to 106 region of the promoter, fragments of
the K8 promoter were placed upstream of the minimal
adenovirus E1b promoter and chloramphenicol acetyltrans-
ferase (CAT) gene. Use of the 187 to 35 promoter
region conferred responsiveness to ORF50. However the
region identified as significant in the 5 deletion experi-
ments (187/106) did not convey ORF50 responsiveness
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to the reporter gene construct. The (146/35) fragment
was able to convey partial ORF50 responsiveness (19-fold).
To further our deletion analysis, small internal deletions
were constructed using pK8Luc-187 (Fig. 2B). An 18-bp
deletion corresponding to a potential E2F transcription-
binding site (pK8Luc1) failed to reduce K8 promoter
responsiveness to ORF50. Neither a 5-bp substitution
(pK8LucMA) nor a 10-bp deletion in a potential NF-B site
(pK8Luc2) significantly decreased luciferase activity. De-
letions, which removed both the E2F and the NF-B sites
(pK8Luc3), abrogated 80% of ORF50 responsiveness in
HeLa cells. Only a modest reduction was seen in cotrans-
fected DG-75 cells (50% of wild-type). A palindrome se-
quence (PAL1) that acts as an ORF50 responsive element
(50RE) has been identified in the K8 promoter (Lukac et al.,
2001; Wang et al., 2001a). Deletion of this region in
pK8Luc4 resulted in a 50% decrease in luciferase activity
in HeLa cells when compared to pK8Luc-187-transfected
cells but no decrease was observed in DG-75 cells. A
second palindrome sequence (PAL2) was identified up-
stream of the PAL1 site (137/98). Deletion of 10 bp at
the 3 end of this palindrome (pK8Luc5) resulted in a
reduction in luciferase activity in both HeLa and DG-75
cells (20%).
Bacterially expressed ORF50 aa 1–377 binds to PAN
promoter
To determine whether ORF50 protein bound to the K8
promoter, ORF50 cDNA encoding amino acids 1–377 was
cloned into the pGEX-2T (Pharmacia) (Fig. 3A). Cultures
of Escherichia coli containing either pGEX-2T or
pGEX50C were induced with IPTG to express recombi-
nant protein. Crude bacterial lysates were obtained and
subjected to immunoblotting with antibody to GST (Fig.
3B). A 68-kDa band was detected in crude lysates obtained
from IPTG-treated E. coli containing pGEX50C. A 27-
kDa band corresponding to GST protein was detected in
lysates from E. coli containing pGEX-2T.
We used a 30-bp probe corresponding to the PAN RRE
(PAN2) (Song et al., 2001) to determine if the fusion pro-
tein, GST50C, had DNA-binding activity. Two bands
were detected when lysate containing GST50C protein
was used in DNA-binding reactions (Fig. 3C). Preincuba-
Fig. 1. ORF50 protein activates the K8 promoter in the absence of other viral proteins. (A) Schematic diagram of K8 genomic clone, pK8GEN. The top line
indicates the region of the KSHV genome contained in pK8GEN. The arrow indicates the transcription start site. The structure of the major K8 transcript
is shown below. The arrowhead indicates the primer (K8PRXT, complement of 74,932–74,950) used for the primer extension experiments shown in (B) and
(C). (B) Identification of K8 mRNA in BCBL-1 by primer extension. BCBL-1 cells were treated with either DMSO (D) or TPA (T). Labeled K8PRXT primer
hybridized with a transcript with a start site at 74,845 bp, as indicated by the circled codon. (C) DG-75 cells were mock transfected (M) or cotransfected with
pK8GEN and either pcDNA3 (C) or pCMV-50 (50). Labeled K8PRXT again hybridized to RNA initiating at 74,845 (circled codon).
74 W.T. Seaman, E.B. Quinlivan / Virology 310 (2003) 72–84
75W.T. Seaman, E.B. Quinlivan / Virology 310 (2003) 72–84
tion of GST50C with unlabeled PAN2 oligomer resulted
in reduced binding by GST50C to PAN RRE. In contrast,
preincubation of GST50C with the irrelevant oligomer,
GBL, failed to inhibit the formation of the GST50C/PAN2
complexes. Preincubation of the GST50C-containing ly-
sate with anti-GST antibody before addition of PAN2 probe
resulted in the disappearance of the major and minor band
but anti-E2F antibody had no effect on the binding of the
GST50C to the PAN2 probe (Fig. 3D).
Bacterial ORF50 does not bind to K8 promoter fragments
Three overlapping segments of the K8 promoter (Fig. 4A)
were used as probes in electrophoretic mobility shift assays
(EMSAs) to determine if ORF50 bound the K8 promoter
elements. No bands were detected by EMSA when either GST
or GST50C lysate were incubated with K8 A/B or K8 H/C
probes (Fig. 4B). Five bands were detected when GST50C
lysate was incubated with K8 G/I probe. These bands were also
present when GST lysate was used in the DNA-binding reac-
tion. Binding reactions with the 50REPAN showed specific
binding to GST50C in each experiment.
ORF50 responsiveness is regulated by positive and
negative cis-acting elements located in PAL2
To more completely characterize ORF50 activation, we
performed fine mapping experiments in the ORF50 re-
sponse region(s) (Fig. 5A). Again, an increase in luciferase
activity was seen in DG-75 cells when the PAL1 was altered
(132% with pK8LucMB). PAL2 consisted of a 39-bp se-
quence with four distinct regions. The external regions, I
(131 to 137) and IV (98 to 104), are 7 bp in length
and complementary to each other. The internal regions II
(121 to 125) and III (111 to 115) are 5 bp in length
and complementary to each other. There are 5-bp interven-
ing sequences that separate each of the four regions. Trans-
version of nt 100 to 104 in region IV of the palindrome
(pK8LucMC) decreased ORF50-dependent transactivation
in both HeLa and DG-75 cells (6 and 18% of the intact
promoter, respectively). Finer mapping of this 5-bp region
was done by making sequential 2-bp mutations. In addition
complimentary mutations were made in region I. The 2-bp
substitution made at 103 and 104 in region IV
(pK8LucMD) resulted in a significant decrease in trans-
fected HeLa cells (16%) but only a moderate decrease in
DG-75 cells (57%). In contrast, the complementary muta-
tion made at 131 and 132 in region I of the palindrome
(pK8LucME) increased activity in DG-75 cells. The 2-bp
mutation at 102 and 101 in region IV (pK8LucMF) and
the complimentary mutation at133 and134 increased in
both HeLa and DG-75 cells (165–213%). While the mutations
at 99 and 100 in region I (pK8LucMH) resulted in a
decrease in activity in HeLa cells (46%), an increase in activity
was again seen in DG-75 cells (135%). Removal of a potential
MEF2-binding site (pK8LucMJ) in region II (125 to 121)
produced an increase in luciferase activity in both HeLa and
DG-75 cells. Mutation of the complementary region (region
III) of the palindrome at 111 to 114 (pK8LucMI) resulted
in a decrease in activity in transfected DG-75 cells (37%).
The K8 promoter fragment, which spanned the PAL2 re-
gion in the EMSAs, described above, interacted with a least
five bacterial proteins. To determine if ORF50-specific binding
was present but masked by the bacterial proteins, we con-
structed smaller oligomer probes for additional binding exper-
iments. Again, GST-ORF50 bound efficiently to the PAN
promoter response element (Fig. 5B). Neither the PAL1 nor
the PAL2 probes demonstrated specific binding activity. It was
possible that the promoter fragments disrupted the binding site
and the oligomer probes were not large enough to include the
entire ORF50-binding site. To address this possibility, we
examined ORF50 binding to a probe with the entire K8 pro-
moter (K8-200). A similar probe containing the PAN promoter
was also constructed (PAN-200). Binding activity was easily
seen with the PAN probe but not with the K8 probe (Fig. 5C).
We concluded that ORF50 activation of the K8 promoter did
not require direct ORF50 binding and was regulated positively
by the right arm of the PAL2 palindrome.
Discussion
The ORF50 gene of KSHV is a homologue of the EBV
BRLF1 and the HVS ORF50 genes. The encoded protein is
Fig. 2. Mapping ORF50 response regions in the K8 promoter. Deletion analysis of the K8 promoter. (A) Various regions of the K8 promoter were PCR
amplified and cloned into the reporter plasmids, pGL2-Basic or pE1bCAT. The map positions for each K8 promoter construct were determined relative to
the K8 transcription start site. HeLa cells were cotransfected with pCMV-50 and each of the K8 promoter constructs. The position of potential cellular
transcription factor-binding sites shown above the pK8Luc-538 construct were identified with MatInspector computer program. Transcription factor
abbreviations: A, AP-1; C, CREB; E, E2F; M, MEF2; N, NF-B; W, winged helix protein. I: ORF50-induced fold increase in luciferase activity was
determined relative to activity in cells cotransfected with each of the luciferase K8 promoter constructs and pcDNA3 and is indicated to the right of each
construct. The187/106 region contained elements responsive to ORF50. -Galactosidase expression from a transfection expression vector was used to
control for variations in transfection efficiency. II: The region identified in (I) was transferred to a adenovirus-minimal promoter construct. Fold increase in
CAT activity was determined relative to activity in cells cotransfected with each of the K8 CAT constructs and pcDNA3. The K8 promoter regions required
for ORF50 activation did not transfer ORF50 responsiveness to an Elb adenovirus minimal promoter construct. (B) Small deletions were generated by PCR
using pK8Luc-187 as a template. The stippled box indicates the ORF57-like palindrome (PAL1). The black box indicates a newly identified palindrome. The
location of potential CREB, E2F, MEF2, and NF-B binding sites in pK8Luc-187 are also shown. Deleted regions of each promoter construct are shown
on the left half of the figure. Luciferase activity relative to the wild-type promoter was determined in HeLa and DG-75 cells and the results are shown to
the right of each construct. Disruption of the region110/100 produced the greatest disruption in ORF50 responsiveness.
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a transactivator of KSHV lytic gene expression and acti-
vates the lytic cascade of this virus (Gradoville et al., 2000;
Lukac et al., 1998, 1999; Miller et al., 1997; Seaman et al.,
1999). In this article we examined ORF50 activation of the
K8 gene and identify novel sequences in the K8 promoter
that are necessary for ORF50-dependent transactivation.
ORF50 expression in KSHV-negative cells (DG-75 cells)
initiated K8 mRNA transcription in the absence of other
viral gene products. We identified a second K8 50RE, the
PAL2 palindrome, which conveyed the majority of ORF50
responsiveness rather than the previously described
50REK8. In contrast to the findings of others (Lukac et al.,
2001; Wang et al., 2001b), we did not observe binding to K8
promoter sequences despite demonstrating sequence-spe-
cific DNA binding in the same experiments.
The discrepancy between our results and those of others
regarding ORF50 binding to the K8 promoter may have
been due to the systems used to produce the recombinant
ORF50 proteins. Previously, a partially purified His-tagged
ORF50 protein expressed by baculovirus was used to per-
form gel shifts. The protein used in this article was a
GST/ORF50 fusion protein in crude bacterial extracts. We
examined many sources of ORF50 for DNA-binding activity.
In our hands, his-tagged bacterial ORF 50 and eukaryotic
sources of ORF50 (transfected or transduced ORF50-express-
ing adenovirus) showed less binding activity than GST-50.
Fig. 3. Recombinant GST50C protein binds to the ORF50 RRE present in the PAN promoter. (A) Cartoon of the construction of the ORF50-GST fusion
protein expression vector. NL: Nuclear localization; Basic: DNA-binding domain; LZ; Leucine zipper; AD: activation domain. (B) Immunoblot of
GST-ORF50 and GST using GST-specific antibody. Bacterial lysates are indicated above each lane. Predicted size of the protein is shown on the right (MW:
molecular weight). (C) PAN oligomer competes for GST50C binding. Bacteria extracts were incubated with 50X unlabeled oligomers for 30 min prior to
the addition of labeled PAN2 probe. Competitors are as follows: G: oligomer corresponding to a region of pGL2-Basic (vector); P: PAN2. Binding reactions
were subjected to polyacrylamide gel electrophoresis and binding complexes were identified by phosphoimaging. Arrows indicate GST ORF50-specific DNA
complexes. (D) Bacterial lysates containing either GST or GST50C were incubated with labeled PAN2 oligomer. For supershift assays lysates were
preincubated with either anti-GST or anti-E2F polyclonal antibody for 30 min before addition of the PAN2 probe.
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However we did establish that the slower mobility com-
plexes represented specific binding by the GST-ORF50 pro-
tein. The ORF50/PAN-specific bands were competed by an
oligomer containing the PAN ORF50 recognition site but
were not competed by an unrelated oligomer. Additionally,
antibody to the GST portion of the fusion protein but not
antibody to E2F interfered with the formation of ORF50–
DNA complexes. We concluded that complex formation
between GST-ORF50C and PAN involved direct protein–
DNA binding, but ORF50 interactions with the K8 pro-
moter are indirect.
Other sources of ORF50 protein may contain a cofac-
tor(s) which facilitated K8 promoter and ORF50 binding.
Sp1 and Oct-1 sites convey ORF50 responsiveness in the
TK and ORF50 promoters, respectively (Sakakibara et al.,
2001; Zhang et al., 1998). An MEF-2 (serum response
factor family) DNA-binding site in the EBV BZLF-1 pro-
moter is required for calcium-mediated activation (Liu et
al., 1997). Sequence analysis of the K8 promoter identified
many sites of potential interaction with known cellular
transactivators. Deletion of either the E2F or the NF-B
sites failed to reduce ORF50-dependent transactivation re-
gardless of cell type, suggesting that these sites, alone, are
not sufficient for ORF50-dependent transactivation. The
E2F site located between 187 and 146 nt of the pro-
moter may explain the loss of promoter activity when this
region was removed. It does not explain all of the decrease
seen with the 146-nt construct since specific deletion of
the E2F site reduced activity only when the downstream
NF-B site was also removed. Mutation of the potential
MEF2 site identified in PAL2 of the K8 promoter resulted in
an increase in ORF50-dependent transactivation. Here, the
MEF2 site functioned as a repressor element and under-
scored the complex nature of K8 gene regulation.
Interactions between ORF50 and cellular factors are
known to occur and may explain our findings. Interactions
between both ORF50 and CREB-binding protein (CBP) and
histone deacetylase (HDAC) have been reported (Gwack et
al., 2001). CBP is a coactivator that forms a bridge between
specific transcription factors and the basal transcription ma-
chinery and HDAC is an enzyme that deacetylates histones
resulting in repression of transcription (Arias et al., 1994;
Bannister and Kouzarides, 1996; Chrivia et al., 1993; Ka-
mei et al., 1996; Ogryzko et al., 1996). These interactions
may alter recruitment of promoter-specific transcription fac-
tors, basal transcription factors, or histone-controlled access
to promoters. The activation domains of EBV BRLF1 and
HVS ORF50 interacted with TATA binding protein (TBP)
Fig. 4. GST50C does not bind to the K8 promoter. (A) The top three lines indicate the position of K8 probes used for DNA-binding reactions. The fourth
line is a schematic representation of pK8Luc-187. The stippled box indicates the position of the ORF57-like palindrome (PALI). The black box indicates the
position of the upstream palindrome (PAL2) (E: E2F; M: MEF2; C: CREB; N: NFKB). (B) Either no extract (0), GST (G), or GST50C (50) lysates were
incubated with the K8A/B, K8GI, or K8H/C probes using PAN2-binding conditions. ORF50/DNA complexes are indicated (*) and are present within the
PAN2 probe in each experiment. GST50/DNA complexes are not seen with K8 promoter fragments.
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Fig. 5. Fine mapping of ORF50-responsive sequences in the K8 promoter. (A) Site-specific changes were made in the newly identified palindrome. The top line
is a schematic representation of pK8Luc-187. The stippled box represents the ORF57-like palindrome (PAL1). The black box indicating the newly identified
palindrome (PAL2) has been expanded to show the sequence. Underlined sequences representing regions I–IV show the position of PAL2. The potential CREB (C),
E2F (E), MEF2 (M), and NF-B (N) binding sites identified by MatInspector are shown above the sequence. Lowercase letters in boxes indicate nucleotide changes
relative to pK8Luc-187. Luciferase activity is shown to the right of each construct and is expressed relative to pK8Luc-187 activity. Recombinant GST50C does
not bind either the PAL1 (P1) or the PAL2 (P2) present in the K8 promoter. No protein (0), GST (G), or GST50C (50) protein was incubated with a labeled K8
probe corresponding to either K8 PAL1, K8 PAL2, or 50REPAN (PAN2) shown in (B) or a probe spanning 200 bp of the K8 (K8-200) or PAN (PAN-200) promoters
shown in (C). GST ORF50/DNA complexes were only seen with PAN2.
79W.T. Seaman, E.B. Quinlivan / Virology 310 (2003) 72–84
(Hall and Whitehouse, 1999; Manet et al., 1993). A novel
cellular protein, K-RBP, was identified by specific interac-
tions with ORF50 (Wang et al., 2001b). K-RBP is a member
of the KRAB-zinc finger protein family, which uses the zinc
finger motif to bind DNA. More recently, ORF50 has also
been shown to interact with the RBP-J protein and induce
transcription through the Notch signaling pathway (Liang et
al., 2002). Interactions with one or more of these factors
may provide an indirect means of K8 activation.
Some sequence homology was identified when PAL2
was compared with PAL1 or 50RE57 (Fig. 6). The PAL2
sequence has not been previously identified as a K8 re-
sponse element. Despite the homology, one notable differ-
ence between PAL2 and the other 50REs is the number of
nucleotides between the palindrome arms. Divergence from
the perfect palindrome sequence is known to affect the
binding affinity of transcription factors and alter promoter
strength (Klinger, 2001). The number of nucleotides be-
tween arms of the estrogen receptor element (ERE) has been
shown to be a critical determinant of ERE responsiveness.
The arms of PAL2 are separated by five nucleotides rather
than the three nucleotides present in PAL1. We demonstrate
a different pattern of responsiveness with PAL1 and ORF50
as compared to PAL2, possibly explained by the sequence
structure of the 50REs.
Despite the occurrence of palindromic sequence in the
50RE, disruption of the right and left arms of PAL2 did not
affect K8 responsiveness equally. An element spanning
103 to 113 in the 3 end of PAL2 resulted in a decrease
in ORF50-dependent transactivation. Constructs with the
complementary mutations in the 5 end did not have this
effect. The second ORF50 response element is not the
palindrome in which it is located but the response element
is hidden within this structure. The MEF-2 site located
within the left arm of the PAL2 site may explain the dif-
ferent effect of the two arms of the palindrome. Mutations
in the 5 end of PAL157 were also less effective in disrupt-
ing ORF50 responsiveness than those in the 3 end. These
observations provide evidence that the 5 and 3 portions of
the repeated elements in ORF50 response elements have
divergent roles.
While some homology between PAL1 and PAL2 50REs
exists, we describe a number of differences. These include
placement of cellular response elements in flanking regions
and spacing of the two arms of the palindromes. Functional
differences, as reflected by divergence in cell-line specific
activity and the function of the arms of the palindromes,
were present as well. Primary sequence and functional dif-
ferences were also seen between the RE in the PAN pro-
moter and those in K8 (sequence and variability in ORF50-
binding activity). The structural and functional variability in
ORF50 response elements indicates that ORF50 utilizes
multiple mechanisms to maintain a tight control over KSHV
lytic replication.
Materials and methods
Cell lines
BCBL-1 (KSHV-positive B-cell lymphoma) (Renne et
al., 1996), DG-75 (EBV-negative, KSHV-negative Burkitt’s
lymphoma) cells were grown in RPMI. HeLa (cervical car-
cinoma) and Cos-7 (monkey kidney) cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM). All cells
were grown with 10% fetal calf serum at 37°C in 5% CO2.
Plasmids
The construction of pCMV-50 was described previously
(Seaman et al., 1999). The series of 5 deletion K8 promoter
constructs was created by inserting PCR-amplified regions
Fig. 6. Sequence comparison of various ORF50 response elements. The ORF50 response regions for K8 PAL2, K8 PAL1, ORF57 PAL1, PAN RRE. The genome
location of each sequence is indicated below the name. Arrows  the location and direction of repeats; boxes  the center position of inverted repeats. Sequences
required for ORF50 responsiveness previously identified by fine mapping are indicated by *(Lukac et al., 2001), **(Duan et al., 2001), and X (this article); and
shading  sequence conserved in three of the four elements. Numbers at the bottom of the figure indicate position in the K8 PAL2 palindrome.
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(Vent Polymerase, New England BioLabs) into pGL2-Basic
(Promega) using the SmaI and SacI sites: pK8Luc-538
(74,313 to 74,851) was created with HHV8.40 (5ATCA-
GAGTCTATTCGCCC3) and PK8C (5GCGGAGCTCA-
ATTTGGCAGGGTTACACGT3); pK8Luc-187 (74,653 to
74,851) with PK8A (5GCGCCCCGGGTT AACTTCC-
CAGGCAGTT3) and PK8C; pK8Luc-146 (74,707 to
74,851) was constructed using a 153-bp HpaI/SacI fragment
from pK8Luc-187; pK8Luc-106 (74,745 to 74,851) was con-
structed using a 113-bp blunt-ended HinfI/SacI fragment from
pK8Luc-187. The fragments 74,667–74,810, 74,707–74,810,
and 74,667–74,734 were inserted upstream of the adenovirus
E1b minimal promoter element in the pGAL4E1bCAT re-
porter plasmid after removing the GAL4 DNA-binding
elements, creating pK8E1bCAT-187, pK8E1bCAT-146,
and pK8E1bCAT187/104 (Martin et al., 1990).
Small internal deletions were made by overlapping PCR
according to the methods of Horton (Horton et al., 1989).
For each mutant, two primary PCRs were performed. Mu-
tant internal forward primers were used in forward primary
PCRs with PK8C. Mutant internal reverse primers were
used in reverse primary PCRs with PK8A. Each mutant
internal forward primer was complementary to its respective
reverse internal primer. Primary PCR products were gel
purified, mixed, and used for secondary PCR. Since internal
mutant primers were complementary, the 3 end of single-
stranded forward primary PCR products were capable of
annealing to the 3 end of single-stranded reverse primary
PCR products at internal primer sequences. This annealing
generated internal deletion mutant K8 promoter fragments
after secondary PCR. All primary forward PCR products
were generated with PK8C as the external primer. All re-
verse primary PCR were performed with PK8A as the
external primer. Secondary PCR products were digested
with SmaI and SacI and inserted into pGL2-Basic. Except
where indicated, pK8Luc-187 was used as the template in
all primary PCRs. All mutants were sequenced: pK8Luc1
(deletion 74,687–74,696) was created with PK8Luc1F
(5GCAGTTTATTTTTAACAGAACCTACAGATTCTA-
CTT3, internal forward primer, InFP) and PK8Luc1R
(5AAGTAGAATCTGTAGGTTCTGTTAAAAATAAAC-
TGA3, internal reverse primer, InRP); pK8Luc2 (deletion
74,687–74,696): PK8Luc2F (5TGTGAAACAATAATGA-
TTATTTCCTCCGTTGTCGAC3, InFP) and PK8Luc2R
(5GTCGACAACGGAGGAAATAATCATTATTGTTTC-
ACA3, InRP); pK8Luc3 (deletion 74,687–74,696 and
74,786–74,797) was made essentially as pK8Luc2 except
that pK8Luc1 was used as the original template in the
primary PCRs; pK8Luc4 (deletion 74,687–74,696): with
PK8Luc4F (5GGTTGATTGTGACTATTTAAAGGGG-
GTGGTATTTCC3, InFP) and PK8Luc4R (5GGAAAT-
ACCACCCCCTTTAAATAGTCACAATCAACC3, RF);
pK8Luc5 (deletion 74,687–74,696); PK8Luc5F (5CTT-
AAAATAGCTCATTTTTGGTTGATTGTGACTATT3,
InFP) and PK8Luc5R (5AATAGTCACAATCAACCA-
AAAATGAGCTATTTTAAG3, InRP).
Site-specific base changes were made using pK8Luc-187
as a template according to the method of Ho et al. (1989).
Mutant plasmids were generated by PCR with the following
internal oligomers: pK8LucMA: PK8LucMAF (5TGTGA-
AACAATAATGATTtccGaGGGTGGTATTTCC3, forward
primer, FP) and PK8LucMAR (5GGAAATACCACCCt-
CggaAATCATTATTGTTTCACA3, reverse primer, RP);
pK8LucMB: PK8LucMBF (5TTGTGAAACAtccgaGATTA-
AAGGG3, FP) and PK8LucMBR (5CCCTTTAATCtcgga-
TGTTTCACAA3, RP); pK8LucMC: PK8LucMCF (5ATT-
TTCTCACtccgaTGGTTGATTG3, FP) and PK8LucMCR
(5CAATCAACCAtcggaGTGAGAAAAT3, RP); pK8LucMD:
PK8LucMDF (5ATTTTCTCACtcATCTGGTTGA3, FP)
and PK8LucMDR (5TCAACCAGATcaGTGAGAAAAT3,
RP); pK8LucME: PK8LucMEF (5ACAGATgaTACTTA-
AAATAG3, FP) and PK8LucMER (5CTATTTTAAG-
TATcaTCTGT3, RP); pK8LucMF: PK8LucMFF (5TTT-
CTCACGAcgCTGGTTGATT3, FP) and PK8LucMFR
(5AATCAACCAGcgTCGTGAGAAA3, RP); pK8LucMG:
PK8LucMGF (5CTACAGcgTCTACTTAAAAT3, FP) and
PK8LucMGR (5ATTTTAAGTAGAcgCTGTAG3, RP);
pK8LucMH: PK8LucMHF (5TCTCACGAATagGGTTG-
ATTGT3, FP) and PK8LucMHR (5ACAATCAACCctA-
TTCGTGAGA3, RP); pK8LucMI: PK8LucMIF (5ATA-
GCTCAccccCTCACGAA3, FP) and PK8LucMIR (5TTC-
GTGAGggggTGAGCTAT3, RP); pK8LucMJ: PK8LucMJF
(5CAGATTCTACTTccccTAGCTCATTTTC3, FP) and
PK8LucMJR (5GAAAATGAGCTAggggAAGTAGAAT-
CTG3, RP). All primary forward PCR products were gen-
erated with PK8C as the external primer. All reverse pri-
mary PCR were performed with PK8A as the external
primer. Primary PCR products were gel purified and used in
secondary PCR. All secondary PCR products were digested
with SmaI and SacI and inserted into the SmaI/SacI sites of
pGL2-Basic.
pK8GEN was constructed by inserting a genomic region
of KSHV from into pBluescript SKII. Primers HHVV8.40
and HHV8.49 (5CGTGGAACGCACAGGTAAAG3) were
used to amplify K8 genomic DNA from BCBL-1 cells. This
product was digested with ApaI (74,348) and EcoRI
(76,469) and inserted into the ApaI/EcoRI sites of pBlue-
script SKII to create pK8GENPA. A 260-bp EcoRI/XbaI
fragment corresponding to 76,470–76,738 was removed
from pCMV-K8 and inserted into the EcoRI/XbaI site of
pK8GENPA to obtain pK8GEN.
pGEX-50C was constructed by inserting a BamHI/
blunt-ended Acc65I fragment from pCMV-50 into the
BamHI/blunt-ended EcoRI sites of pGEX-2T. Maintenance
of the correct reading frame at the GST/ORF50 junction
was confirmed by DNA sequencing.
DNA transfection
BCL-1 cells were treated with tetradecanoyl phorbol
acetate or vehicle alone. HeLa cells were seeded into six
well plates at 2  105 cells/well 24 h before transfection.
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Cells were transfected with 0.25 mg pCMV (Clontech), 1
g of reporter plasmid, and either 1 g of pcDNA3 or
pCMV-50 using Superfect (Qiagen) according to the man-
ufacturer’s instructions. DG-75 cells were transfected by
electroporation using a Bio-Rad gene pulser as previously
described (Seaman et al., 1999).
Primer extension
DG-75 cells were cotransfected with pK8GEN and either
pcDNA3 or pCMV-50. The primer, K8PRXT (5TGC-
CCGTTGAGGCTTAGA3), corresponding to the comple-
ment of 74,932–74,950, was mixed with 10 g of total RNA
(isolated at 48 h) and 0.5 mM deoxynucleotide mix, incu-
bated at 75°C for 5 min, and slowly cooled to 42°C. Primer
extension was performed at 42°C using Superscript II re-
verse transcriptase (Gibco-BRL). The DNA was precipi-
tated with ethanol and resuspended in running buffer (95%
formamide, 20 mM EDTA, 0.05% bromphenol blue, 0.02%
xylene cyanol), heated to 95°C for 10 min, and run on a 6%
polyacrylamide sequencing gel containing urea. A DNA
ladder was generated by sequencing pK8GEN with
K8PRXT.
Reporter gene assays
CAT assays were performed as previously described
(Seaman et al., 1999). Luciferase activity was determined
48 h after transfection, by adding 50 l of cell lysate to 10
l of luciferase substrate and determining luminescence
using the luminometer of a Wallac VICTOR2 multilabel
counter (Luciferase assay kit, Promega). -Galactosidase
activity was determined with a Gal-Screen chemilumines-
cent reporter gene kit (Tropix) and used to normalize lucif-
erase assay results.
Electrophoretic mobility shift assay
E. coli BL21 bacteria were transformed with pGEX-2T
or pGEX-50C. Bacteria were grown in LB medium con-
taining 50 g/l ampicillin and grown at 37°C to an OD
A600 of 0.6–0.8. IPTG was added to a final concentration of
1 mM and cells were incubated at 30°C for 3 h. Bacterial
lysates, prepared by sonication, were analyzed by SDS–
PAGE, Coomassie blue staining, and immunoblotting with
an anti-GST antibody (Sigma). EMSA was performed as
described by Song (Song et al., 2001). Ten micrograms of
crude bacteria extract was incubated with 32P-labeled probe
in 1X binding buffer (10 mM Tris, pH, 150 mM KCl, pH
7.5 mM MgCl2, 1 mM EDTA, 0.5 mM DTT, 50 mM
-mercaptoethanol, 5 g bovine serum albumin, 4 g
salmon sperm DNA) on ice for 30 min. For competition and
supershift assays, lysates were incubated with cold compet-
itor oligonucleotides or anti-GST antibody, respectively, in
binding buffer on ice for 30 min prior to the addition of
the 32P probe. Binding reactions were run on a 1X TGE,
5% polyacrylamide gel containing 5% glycerol at 4°C.
Gels were dried and bands were detected by phosphor-
imaging. Oligomer used to construct probes were as
follows: PAN2F-, 5GGGAAATGGGTGGCTAACCT-
GTCCAAAATATG3; PAN2R-, 5GGGCATATTTTG-
GACAGGTTAGCCACCCATTT3; K8PAL1F-, 5GGG-
ATTTGTGAAACAATAATGATTAAA3; K8PAL1R-,
5GGGCCCCTTTAATCATTATTGTTTCA3; K8PAL2F-,
5GGGAACCTACAGATTCTACTTAAAATAGCTCAT-
TTTCTCACGAATCTG3; K8PAL2R-, 5GGGATCAAC-
CAGATTCGTGAGAAAATGAGCTATTTTAAGTAGA-
ATCTG3.
Western blot analysis of bacteria lysates GST50 C protein
One hundred nanograms of crude bacteria was subjected
to SDS–PAGE and proteins were blotted to nitrocellulose
filter paper. The membrane was blocked by incubating with
1% blocking reagent (Roche) in 1X TBST (50 mM Tris, pH
7.5, 150 mM NaCl, 0.05% Tween 20) for 1 h at room
temperature. The membrane was incubated with rabbit anti-
GST antibody (Sigma) diluted 1:1000 in TBST for 1 h at
room temperature. The membrane was washed with 1X
TBST and incubated with a 1:1000 dilution of mouse anti-
rabbit antibody conjugated to horseradish peroxide for 1 h at
room temperature. The membrane was washed with 1X
TBS (50 mM Tris, pH 7.5, 150 mM NaCl) and proteins
were detected with an ECL western blotting detection kit
(Amersham).
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